Characteristic | Polaprezinc (n = 10) | Control (n = 10) | Pvalue |
---|---|---|---|
Sex ratio (male/female) | 9/1 | 7/3 | N.S.* |
Age (years); median (range) | 78.5 (64-82) | 75.5 (62-86) | N.S.** |
Hemoglobin concentration (g/dL); median (range) | 13.6 (10.2-15.3) | 13.7 (8-15) | N.S.** |
Indication for low-dose aspirin therapy | Ā | Ā | Ā |
āValvular heart disease | 3 | 2 | Ā |
āStroke | 3 | 7 | N.S.* |
āOther | 4 | 1 | Ā |
Duration of low-dose aspirin (months); median (range) | 64.5 (24-120) | 48 (36-120) | N.S.** |
Anti-ulcer drug | Ā | Ā | Ā |
āH2 blocker | 1 | 2 | N.S.* |
āPPI | 3 | 1 | Ā |
āNone | 6 | 7 | Ā |
Initial CE findings | Ā | Ā | Ā |
āMedian number of erosions/ulcers (range) | 2 (0-6) | 2 (0-10) | N.S.** |
āMedian number of reddened lesions (range) | 3 (0-7) | 2 (0-7) | N.S.** |
CE score | Ā | Ā | Ā |
āMedian score (range) | 180 (0-450) | 225 (0-225) | N.S.** |
āCE score by category | Ā | Ā | Ā |
āāNormal or clinically insignificant change (<135) | 3 | 4 | Ā |
āāMild change (ā„135 and <790) | 7 | 6 | N.S.* |
āāModerate or severe change (ā„790) | 0 | 0 | Ā |